Quantcast
Home > Quotes > KRYS

Krystal Biotech, Inc. Common Stock (KRYS) Quote & Summary Data

KRYS 
$42.66
*  
1.48
3.59%
Get KRYS Alerts
*Delayed - data as of Aug. 16, 2019  -  Find a broker to begin trading KRYS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    KRYS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
67
Today's High / Low
$ 43.02 / $ 40.22
Share Volume
103,088
50 Day Avg. Daily Volume
263,407
Previous Close
$ 41.18
52 Week High / Low
$ 51.6699 / $ 14.30
Market Cap
738,034,637
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.21

Intraday Chart

Shares Traded

Share Volume:
103,088
50 Day Avg. Daily Volume:
263,407

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.20

Trading Range

The current last sale of $42.66 is 198.32% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 43.02 $ 51.6699
 Low: $ 40.22 $ 14.30

Company Description (as filed with the SEC)

Krystal Biotech, Inc. (the "Company," "we," or "us," or other similar pronouns) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. We have developed a proprietary gene therapy platform, which we refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of an engineered, patented (issued and pending), viral vector based on modified herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which we believe there are no known effective treatments. We are initially using our STAR-D platform to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene, and plan to leverage our platform in the future to expand our pipeline to include other dermatological indications and skin conditions.  ... More ...  



Risk Grade

Where does KRYS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 41.47
Open Date:
Aug. 16, 2019
Close Price:
$ 42.66
Close Date:
Aug. 16, 2019


Consensus Recommendation

Analyst Info